Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/20954
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChatzikyriakidou, A.en
dc.contributor.authorGeorgiou, I.en
dc.contributor.authorVoulgari, P. V.en
dc.contributor.authorPapadopoulos, C. G.en
dc.contributor.authorTzavaras, T.en
dc.contributor.authorDrosos, A. A.en
dc.date.accessioned2015-11-24T19:11:45Z-
dc.date.available2015-11-24T19:11:45Z-
dc.identifier.issn0172-8172-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/20954-
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectArthritis, Rheumatoid/drug therapy/geneticsen
dc.subjectCohort Studiesen
dc.subjectFemaleen
dc.subjectFolic Acid Antagonists/ pharmacologyen
dc.subjectHumansen
dc.subjectMaleen
dc.subjectMembrane Transport Proteins/ genetics/ metabolismen
dc.subjectMethotrexate/ pharmacologyen
dc.subjectMiddle Ageden
dc.subjectPolymorphism, Single Nucleotide/geneticsen
dc.subjectReduced Folate Carrier Proteinen
dc.subjectRegulatory Elements, Transcriptional/ geneticsen
dc.subjectTreatment Failureen
dc.titleTranscription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1007/s00296-007-0339-0-
heal.identifier.secondaryhttp://link.springer.com/content/pdf/10.1007%2Fs00296-007-0339-0.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2007-
heal.abstractThe reduced folate carrier (RFC) protein (SLC19A1-gene) has central role in the uptake and intracellular accumulation of folates. In this respect, we investigate whether SLC19A1 genetic variations could affect rheumatoid arthritis (RA) patient response to antifolate treatment. One hundred six unrelated RA patients were enrolled in this study. Polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) was used as the screening method for genetic variants. Unusual SSCP patterns were characterized by direct sequencing of the PCR products and subsequently restriction assays were established. Western blot analysis of RFC protein was performed in respect of the identified SLC19A1 genotypes. Patient response to methotrexate (MTX) was evaluated using disease activity for 28 joint indices score, American College of Rheumatology 20% and 50% scores. No mutation was found in the SLC19A1 gene, but three polymorphic variants: the -43T>C in the 5'-flanking sequence to the ATG-transcription start site; and the 80G>A (R27H) and 696C>T (P232P) in the coding gene sequence. The wild type alleles of the three polymorphisms were in strict linkage disequilibrium. Western blot analysis revealed that the non-wild type allele of polymorphism -43T>C is associated with low RFC protein expression levels. Furthermore, the genotypic analysis of the functional polymorphic variant -43T>C revealed to be insufficient to predict patient response to MTX therapy. According to recent literature, several transport systems account for folate membrane transport. Additionally, in previous studies discrepancies have been reported to exist between the same genetic variants and their use in prediction of patient response to MTX therapy. Therefore, the present genotypic-phenotypic association study of a functional polymorphism revealed the need of a complex genotypic analysis in order to predict patient response to folate antagonists' therapy.en
heal.journalNameRheumatol Inten
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
File Description SizeFormat 
Chatzikyriakidou-2007-Transcription regula.pdf270.35 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons